+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
BLISSGVS

Bliss GVS Pharma Share Price

₹655.95 -11.75 (-1.76%)
455.89% Gain from 52W Low

09 Oct, 2026 3:31 PM (IST)

Bliss GVS Pharma live price: ₹655.95. It opened at ₹667 vs previous close ₹668; intraday high/low: ₹667/₹634. The 50 & 200 DMA stand at ₹621.90/₹427.20.

Bliss GVS Pharma Performance

  • Today's Low
  • ₹634
  • Today's High
  • ₹667
  • 52 Week Low
  • ₹118
  • 52 Week High
  • ₹740
  • Open Price₹667
  • Previous Close₹668
  • Volume169,483
  • 50 DMA₹621.90
  • 100 DMA₹538.40
  • 200 DMA₹427.20

Bliss GVS Pharma Chart

Investment Returns

  • Over 1 Month -9.02%
  • Over 3 Month + 25.11%
  • Over 6 Month + 153.3%
  • Over 1 Year + 312.03%

Smart Investing Starts Here Start SIP with Bliss GVS Pharma for Steady Growth!

Invest Now

Bliss GVS Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 51.2
  • PEG Ratio
  • 1.8
  • Market Cap Cr
  • 6,975
  • P/B Ratio
  • 5.6
  • Average True Range
  • 33.4
  • EPS
  • 12.8
  • Dividend Yield
  • 0.2
  • MACD Signal
  • 13.5
  • RSI
  • 48.07
  • MFI
  • 71.07

Latest Stock News Updates

Bliss GVS Pharma Ltd - 506197 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Please find enclosed herewith the certificate under Regulation 74(5) of SEBI(DP) Regulations, 2018 for the quarter ended September 30, 2026.

Bliss GVS Pharma Ltd - 506197 - Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011

The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Catalyst Trusteeship Ltd

Bliss GVS Pharma Ltd - 506197 - Board Meeting Outcome for Outcome Of Board Meeting Pursuant To Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations")

Please find enclosed herewith the outcome of the Board Meeting held today i.e. Thursday, October 01, 2026 through Video Conferencing or Other Audio Visual Means.

Bliss GVS Pharma Financials

Bliss GVS Pharma Technicals

EMA & SMA

Current Price
₹655.95
-11.75 (-1.76%)
pointer
  • Bearish Moving Average 9
  • Bullish Moving Average 7
  • 20 Day
  • ₹674.20
  • 50 Day
  • ₹621.90
  • 100 Day
  • ₹538.40
  • 200 Day
  • ₹427.20

Resistance and Support

652.48 Pivot Speed
  • R3 703.30
  • R2 685.20
  • R1 670.60
  • S1 637.80
  • S2 619.70
  • S3 605.10

Bliss GVS Pharma Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-10-01 Employees Stock Option Plan
2026-08-12 Quarterly Results
2026-05-12 Audited Results & Final Dividend
2026-02-10 Quarterly Results & Interim Dividend
2025-11-06 Quarterly Results
Date Purpose Remarks
2026-07-08 FINAL Rs.1.00 per share(100%)Final Dividend
2026-02-18 INTERIM Rs.0.50 per share(50%)Interim Dividend
2025-07-24 FINAL Rs.0.50 per share(50%)Final Dividend
View Bliss GVS Pharma Dividend History Arrow
Date Purpose Remarks
2008-03-18 Split Stock Split from Rs. 10/- to Re. 1/-.

Bliss GVS Pharma Shareholding Pattern

47.45%
35.01%
9.2%
8.07%
0.26%

About Bliss GVS Pharma

Bliss GVS Pharma is engaged in manufacturing, marketing, trading and export of pharmaceutical products. The Company is one of among the world leaders in Suppositories and Pessaries dosage forms with one of the largest portfolios in this segment. View More
  • NSE Symbol
  • BLISSGVS
  • BSE Symbol
  • 506197
  • ISIN
  • INE416D01022

Similar Stocks to Bliss GVS Pharma

Bliss GVS Pharma FAQs

Bliss GVS Pharma share price is ₹655 As on 12 October, 2026 | 07:23

The Market Cap of Bliss GVS Pharma is ₹6974.7 Cr As on 12 October, 2026 | 07:23

The P/E ratio of Bliss GVS Pharma is 51.2 As on 12 October, 2026 | 07:23

The PB ratio of Bliss GVS Pharma is 5.6 As on 12 October, 2026 | 07:23

The 52 week High & Low of Bliss GVS Pharma is ₹739.9/₹118 respectively As on 12 October, 2026 | 07:23

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23